Dr. Goncalves, former CMO at Cara Therapeutics, joins Oruka as CMO Eugenia Levi, PharmD, former Head of Global Medical Affairs for Cosentyx at Novartis, also joins as VP, Medical Affairs ...
STAMFORD, Conn., April 02, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of...
Cara Therapeutics to Host NP Virtual KOL Event on Wednesday, March 27, 2024
Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
STAMFORD, Conn., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) today announced the Company will host a conference call and live audio webcast on Monday, March 4, 2024, at...
Focus on Phase 2/3 program in notalgia paresthetica (NP), a neuropathic disorder with significant unmet need Phase 3 program in advanced chronic kidney disease (CKD) to be discontinued ...
Despite having an FDA-approved injectable product, pruritus-focused drug developer Cara Therapeutics is laying off up to half of its staff as it narrows its clinical ambitions.
Oral difelikefalin as adjunct to topical corticosteroids (TCS) did not demonstrate meaningful clinical benefit compared to TCS alone; As a result, Cara will discontinue its clinical program in...
“ Non-dilutive financing agreement with HealthCare Royalty for up to $40 million expected to extend cash runway into 2025 “ “ Key data readouts for all three late-stage oral difelikefalin clinical...
Transaction supports progression of late-stage oral difelikefalin clinical programs Non-dilutive capital expected to extend cash runway into 2025 STAMFORD, Conn., Nov. 02, 2023 (GLOBE NEWSWIRE) --...